Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Modulation of ITK signaling for sustainable adoptive T cell therapy

Award Number: R21CA283872
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Modulation of ITK signaling for sustainable adoptive T cell therapy - Project Summary/Abstract CAR-T cell therapy has demonstrated success in curing B cell (CD19+) malignancies and has shown promise in treating lupus. However, the cytotoxic and short-lived nature of CAR-T cells results in severe side effects of immunopathology and reduces the therapeutic values of this costly therapy. There is an urgent need for novel strategies to elicit potent and persistent tumor-specific effector and memory T cell responses and minimize off-target toxicity in CAR-T therapy. This makes our work highly significant. T cell development, function and homeostasis are regulated by T cell receptor (TCR) signals as well as cytokines and are suggested to be proportional to TCR signal strength. Yet, excessive TCR activation and cytokine stimulation can trigger excessive cytotoxic T cell activation causing immunopathology, with rapid exhaustion of anti-tumor immunity. Our preliminary data show that IL-2-inducible T cell kinase (ITK), a key regulator of TCR signaling, negatively regulates CD8+ T cell homeostatic expansion and effector memory functions. The absence of ITK resulted in enhanced effector cell fate programming, antigen sensitivity and anti-tumor immunity of CD8+ T cells in mice. Our pilot experiments show that deletion of ITK in human CAR-T cells also resulted in improved production of CAR-T cells that are significantly more sustainable in vitro, and have adequate tumor killing activity and minimal tissue cytotoxicity. We hypothesize that ITK signaling can be modulated to promote CAR-T cell expansion, survival and long-term anti-tumor activity, while limiting the effector cytotoxicity. We propose two specific aims: (1) determine ITK's role in CAR-T cell expansion, function, and safety; and (2) develop a novel class of CAR molecules containing modulatory domains for ITK signaling inhibition. Our work is innovative, supported by exciting preliminary data that challenge conventional thinking. Validating this hypothesis will unveil ITK's role, relevant signaling pathways, and biomarkers in CAR-T cell production, safety, and efficacy. We also propose developing a novel class of CAR molecules that contain TCR signaling modulators, which will further our understanding of CAR-T cell signaling and enable a handy production of safe, effective and sustainable CAR-T cells. Completion of the proposed work will add to our knowledge of new molecular principles for the design of improved CAR-T cell production, safety and therapeutic efficacy. Our pre-clinical results are directly transferable to understanding human CAR-T cell biology and have the potential of improving of CAR-T therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Cancer Biology Research	000	2	3/9/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $210,375 )
2025	2025	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Cancer Biology Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$21,037
2025	2025	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Cancer Biology Research	000	2	3/7/2025	NON-COMPETING CONTINUATION	$189,338
														Subtotal = $210,375

Issue Date FY: 2024 ( Subtotal = $175,313 )
2024	2024	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Cancer Biology Research	000	1	3/12/2024	NEW	$175,313
														Subtotal = $175,313

Grand Total All Awards = $385,688

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulation of ITK signaling for sustainable adoptive T cell therapy

Award Number: R21CA283872

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer